Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial

NCT03297593 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03297593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03297593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2017
Completion date
April 30, 2025
Enrollment
74 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma